ELDN Eledon Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1404281 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.6%
TTM EPS YoY-586.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-257.1%
ROA-71.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets34.5%
Debt / equity0.00x
Current ratio6.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $66.27M | $51.96M |
| SG&A expense | $16.98M | $18.61M |
| Pretax income | -$45.58M | -$35.75M |
| Income tax | $35,000 | $431,000 |
| Net income | -$45.62M | -$36.18M |
| EPS (basic) | -0.52 | -0.66 |
| EPS (diluted) | -0.52 | -0.66 |
| Weighted avg. shares (diluted) | 81.84M | 48.54M |
| Balance sheet | ||
| Cash & equivalents | $22.81M | $20.55M |
| Short-term investments | $110.53M | $119.63M |
| Current assets | $135.69M | $143.73M |
| Total assets | $169.01M | $177.41M |
| Current liabilities | $18.34M | $11.58M |
| Total liabilities | $32.23M | $59.27M |
| Shareholders' equity | $81.08M | $62.45M |
| Shares outstanding | 75.43M | 59.79M |
| Cash flow statement | ||
| Operating cash flow | -$62.34M | -$47.27M |
| Investing cash flow | $10.79M | -$70.31M |
| Financing cash flow | $53.81M | $133.52M |
| Stock-based compensation | $10.45M | $13.12M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.